

# April Ingram

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9555696/april-ingram-publications-by-year.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

7 papers	858 citations	5 h-index	7 g-index
7 ext. papers	998 ext. citations	7.2 avg, IF	2.92 L-index

#	Paper	IF	Citations
7	Effect of spironolactone use in pulmonary arterial hypertension - analysis from pivotal trial databases. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 20458940211045618	2.7	1
6	Spironolactone in pulmonary arterial hypertension: results of a cross-over study. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894019898030	2.7	14
5	Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 734-739	7.1	5
4	Circulating Aldosterone Levels and Disease Severity in Pulmonary Arterial Hypertension. <i>Journal of Pulmonary &amp; Respiratory Medicine</i> , <b>2015</b> , 5,	0	13
3	Collagen Metabolism Biomarkers and Health Related Quality of Life in Pulmonary Arterial Hypertension. <i>International Journal of Cardiovascular Research</i> , <b>2015</b> , 4,	0	8
2	Circulating collagen biomarkers as indicators of disease severity in pulmonary arterial hypertension. <i>JACC: Heart Failure</i> , <b>2014</b> , 2, 412-21	7.9	48
1	Tadalafil therapy for pulmonary arterial hypertension. <i>Circulation</i> , <b>2009</b> , 119, 2894-903	16.7	769